TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
TuHURA Biosciences (NASDAQ:HURA) announced two abstracts accepted for poster presentation at the 2025 AACR Annual Meeting in Chicago. The presentations will showcase:
1. Initial results from a Phase 1 study of KVA12123, an anti-VISTA antibody, both as monotherapy and in combination with pembrolizumab for advanced solid tumors, presented by Kineta's CSO.
2. Mechanistic insights into IFx-Hu2.0 therapy responses in patients with prior anti-PD-1 therapy failure in advanced melanoma, presented by Moffitt Cancer Center scientists.
The company also referenced its previously announced definitive agreement from December 11, 2024, to acquire Kineta, including rights to KVA12123, through a merger expected to close in Q2 2025, subject to funding and other closing conditions.
TuHURA Biosciences (NASDAQ:HURA) ha annunciato l'accettazione di due abstract per presentazioni poster al 2025 AACR Annual Meeting di Chicago. Le presentazioni mostreranno:
1. Risultati iniziali di uno studio di Fase 1 su KVA12123, un anticorpo anti-VISTA, sia come monoterapia che in combinazione con pembrolizumab per tumori solidi avanzati, presentato dal CSO di Kineta.
2. Approfondimenti meccanistici sulle risposte alla terapia IFx-Hu2.0 in pazienti con fallimento della terapia anti-PD-1 precedente in melanoma avanzato, presentati da scienziati del Moffitt Cancer Center.
La società ha anche fatto riferimento al suo accordo definitivo precedentemente annunciato del 11 dicembre 2024, per acquisire Kineta, inclusi i diritti su KVA12123, tramite una fusione che si prevede si concluderà nel secondo trimestre del 2025, soggetta a finanziamenti e altre condizioni di chiusura.
TuHURA Biosciences (NASDAQ:HURA) anunció la aceptación de dos resúmenes para presentación en cartel en el 2025 AACR Annual Meeting en Chicago. Las presentaciones mostrarán:
1. Resultados iniciales de un estudio de Fase 1 de KVA12123, un anticuerpo anti-VISTA, tanto como monoterapia como en combinación con pembrolizumab para tumores sólidos avanzados, presentado por el CSO de Kineta.
2. Perspectivas mecanicistas sobre las respuestas a la terapia IFx-Hu2.0 en pacientes con fracaso previo de terapia anti-PD-1 en melanoma avanzado, presentadas por científicos del Moffitt Cancer Center.
La empresa también hizo referencia a su acuerdo definitivo previamente anunciado del 11 de diciembre de 2024, para adquirir Kineta, incluidos los derechos sobre KVA12123, a través de una fusión que se espera cierre en el segundo trimestre de 2025, sujeto a financiamiento y otras condiciones de cierre.
TuHURA Biosciences (NASDAQ:HURA)는 시카고에서 열리는 2025 AACR 연례 회의에서 포스터 발표를 위해 두 개의 초록이 수락되었다고 발표했습니다. 발표 내용은 다음과 같습니다:
1. KVA12123의 1상 연구 초기 결과로, 이는 항-VISTA 항체로서 단독 요법 및 pembrolizumab과의 병용 요법으로 진행되며, Kineta의 CSO가 발표합니다.
2. 진행성 흑색종에서 이전 항-PD-1 요법 실패 환자에 대한 IFx-Hu2.0 치료 반응에 대한 기전적 통찰을 Moffitt Cancer Center의 과학자들이 발표합니다.
회사는 또한 2024년 12월 11일에 발표된 Kineta 인수에 대한 최종 계약을 언급했으며, 이는 KVA12123에 대한 권리를 포함하며, 2025년 2분기에 종료될 것으로 예상되는 합병을 통해 이루어질 예정입니다. 이는 자금 조달 및 기타 종료 조건에 따라 달라질 수 있습니다.
TuHURA Biosciences (NASDAQ:HURA) a annoncé l'acceptation de deux résumés pour présentation sous forme de poster lors de la 2025 AACR Annual Meeting à Chicago. Les présentations mettront en avant :
1. Les résultats initiaux d'une étude de Phase 1 sur KVA12123, un anticorps anti-VISTA, à la fois en monothérapie et en combinaison avec le pembrolizumab pour des tumeurs solides avancées, présentés par le CSO de Kineta.
2. Des aperçus mécanistes sur les réponses à la thérapie IFx-Hu2.0 chez des patients ayant échoué à une thérapie anti-PD-1 antérieure dans un mélanome avancé, présentés par des scientifiques du Moffitt Cancer Center.
L'entreprise a également fait référence à son accord définitif précédemment annoncé du 11 décembre 2024 pour acquérir Kineta, y compris les droits sur KVA12123, par le biais d'une fusion qui devrait se conclure au deuxième trimestre 2025, sous réserve de financement et d'autres conditions de clôture.
TuHURA Biosciences (NASDAQ:HURA) gab bekannt, dass zwei Abstracts für Posterpräsentationen auf dem 2025 AACR Annual Meeting in Chicago akzeptiert wurden. Die Präsentationen werden Folgendes zeigen:
1. Erste Ergebnisse einer Phase-1-Studie zu KVA12123, einem Anti-VISTA-Antikörper, sowohl als Monotherapie als auch in Kombination mit Pembrolizumab für fortgeschrittene solide Tumoren, präsentiert vom CSO von Kineta.
2. Mechanistische Einblicke in die Therapieantworten von IFx-Hu2.0 bei Patienten mit vorherigem Versagen der Anti-PD-1-Therapie bei fortgeschrittenem Melanom, präsentiert von Wissenschaftlern des Moffitt Cancer Center.
Das Unternehmen verwies auch auf seine zuvor am 11. Dezember 2024 bekannt gegebene endgültige Vereinbarung zur Übernahme von Kineta, einschließlich der Rechte an KVA12123, durch eine Fusion, die voraussichtlich im 2. Quartal 2025 abgeschlossen werden soll, vorbehaltlich der Finanzierung und anderer Abschlussbedingungen.
- Advancing clinical development with Phase 1 study results for KVA12123
- Strategic expansion through pending Kineta acquisition, adding KVA12123 to portfolio
- Multiple clinical programs progressing (KVA12123 and IFx-Hu2.0)
- Merger completion dependent on securing funding conditions
- Both presented therapies still in early clinical stages
Details of the accepted abstracts are as follows:
Title: Initial results from a first in human phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors
Track: Experimental and Molecular Therapeutics
Session: PO.CT01.03 - Phase 0 and Phase I Clinical Trials
Abstract Number: CT041/ 20
Presenter: Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta
Date and Time: April 28, 2025, 9:00 AM – 12:00 PM ET
Location: Section 29
Title: Mechanistic insights into IFx-Hu2.0 responses in the first human trial after prior anti-PD-1 therapy failure
Track: Immunology
Session: PO.IM01.07 - Enhanced Antibodies, TCR Constructs, Cytokines and Chimeric Proteins
Abstract Number: 3428 / 23
Presenter: Joseph Markowitz, M.D., Ph.D.
Date and Time: April 28, 2025, 2:00 PM – 5:00 PM ET
Location: Section 35
For more and to view the abstract, visit the AACR Annual Meeting website.
As previously announced, on December 11, 2024, TuHURA entered into a definitive agreement with Kineta, Inc. (OTC Pink: KANT) ("Kineta"), in which TuHURA would acquire Kineta, including the rights to Kineta's novel KVA12123 antibody, for a combination of cash and shares of TuHURA common stock via a merger transaction. The merger is currently targeted to close in Q2 2025 pending the satisfaction of funding conditions and other closing conditions.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist product candidates, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
IMPORTANT ADDITIONAL INFORMATION
In connection with the proposed acquisition by merger of Kineta, Inc. ("Kineta") by TuHURA (the "Merger"), TuHURA filed with the
A definitive copy of the Joint Proxy Statement/Prospectus will be mailed to Kineta and TuHURA stockholders when that document is final. Investors and stockholders will be able to obtain free copies of the documents filed or that will be filed with the SEC by TuHURA, when they become available, through the website maintained by the SEC at www.sec.gov. The documents filed by TuHURA with the SEC may also be obtained free of charge at TuHURA's website at www.tuhurabio.com or upon written request to: TuHURA, 10500 University Drive, Suite 110,
NO OFFER OR SOLICITATION
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Merger and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy the securities of TuHURA or Kineta, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
PARTICIPANTS IN THE SOLICITATION
TuHURA and Kineta and their respective directors and officers and other members of management may, under SEC rules, be deemed to be participants in the solicitation of proxies from stockholders in connection with the Merger and other matters that may be set forth in the Joint Proxy Statement/Prospectus. Information about TuHURA's directors and executive officers is set forth in TuHURA's filings with the SEC, including TuHURA's Form 10-K filed on March 31, 2025. Additional information regarding the direct and indirect interests, by security holdings or otherwise, of those persons and other persons who may be deemed participants in the solicitation of proxies in the Merger may be obtained by reading the Joint Proxy Statement/Prospectus when it becomes available. You may obtain free copies of these documents as described above under "IMPORTANT ADDITIONAL INFORMATION".
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to express or implied statements regarding TuHURA's expectations, hopes, beliefs, intentions or strategies regarding the future and include, without limitation, statements regarding TuHURA's IFx-Hu2.0 product candidate and anticipated Phase 3 trial, its tumor microenvironment modulators development program, its potential acquisition by merger of Kineta Inc. and the statements about Kineta's VISTA-101 development program and statements regarding the closing conditions for the transaction, TuHURA's needs and expectations regarding its existing capital resources and its need for additional capital, and any developments or results in connection therewith and the anticipated regulatory pathway and timing of the foregoing development programs, studies and trials. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on the combined company's website, and at www.sec.gov.
The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.
Investor Contact:
Dan Dearborn
CFO
813-875-6600
View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-announces-abstracts-accepted-for-poster-presentation-at-the-2025-aacr-annual-meeting-302422765.html
SOURCE TuHURA Biosciences, Inc.
FAQ
What are the two abstracts TuHURA (HURA) is presenting at AACR 2025?
When and where will TuHURA's (HURA) AACR 2025 presentations take place?
What is the status of TuHURA's (HURA) acquisition of Kineta?
What therapeutic candidates will be discussed in TuHURA's (HURA) AACR presentations?
